Medium-term plans, capital spending, new plants, products and drug approvals from Japanese companies.
Hokkaido Electric Power says the Tomari seawall will cost ¥125.5bn and still finish in August 2027, with schedule pressure from overlapping safety works in a cramped site and no earnings impact yet disclosed.
Fujimi's six-year plan targets ¥138.0bn in sales by the year to March 2032 and ¥130bn of capital spending, but the Taiwan plant is still at site selection and the capacity projects lack final investment decisions.
Star Seeds' subsidiary will supply 200 servers to a Korean data center, with estimated sales of ¥13.1bn excluding a separate storage leg, but the company withholds counterparties and prices and leaves its forecast unchanged.
Ono Pharmaceutical will pay Biohaven $80mn upfront, $20mn in development milestones and a royalty of about 20% of sales for Asian rights to three IgG-degrading drugs, led by BHV-1300, now in phase 3 for Graves' disease.
Mr Max Holdings cut its final-year sales target to ¥185bn and its margin goal to 4.5% because construction costs leave fewer sites meeting its return criteria, while existing-store targets stay at ¥160bn and 5.0%.
Imasen Electric plans to move all Wuhan production to Guangzhou by the end of March 2027, expects a special loss of about ¥1.2bn, and keeps its annual forecast because a separate investment-securities gain is expected in the same year.
Japan's health ministry has said Stella Pharma's application to extend Steboronine to recurrent meningioma will go before a pharmaceutical affairs council committee, a review step rather than an approval, on a label wider than the high-grade patients in its trial.
Otsuka's US arm completed its rolling submission on October 6 seeking traditional FDA approval for VOYXACT in adult IgA nephropathy, a drug already approved on an accelerated basis; the company kept its 2026 forecast unchanged.
NPC's five-year plan targets at least 60% of sales from customers other than First Solar, about ¥4bn of investment and a 25% dividend payout ratio, with perovskite and panel recycling as the growth bets.
Nissan Chemical has registered a wholly owned subsidiary in Zhangjiagang with 210mn yuan of registered capital to make BARC and multilayer semiconductor materials near Chinese customers, with a first remittance of 89mn yuan planned for 15 October.
Harima Chemicals Group will stop production at LAWTER (N.Z.) on 30 June 2027 and close the plant in May 2028, expecting a roughly ¥2.8bn special loss after three years of operating losses at the unit.
Direava's endoscopic-surgery language model scored 84.7% for anatomical accuracy and 82.9% for clinical usefulness in an operating-room trial, on a benchmark the company designed, and the company plans to start with surgical education.
A NEDO-led consortium says its droplet system, applied to campus soil, yielded an enzyme 2.4 times as active as a commercial one, with commercial release of the integrated system planned for the end of fiscal 2027.
Ricoh's eight outside officers will review profit structure, business portfolio and capital allocation through the second half of the fiscal year, reporting to a board that says it has decided no specific measures.
Kawasaki Heavy now sees defence revenue of ¥700bn to ¥800bn in the 2030 fiscal year, up from ¥500bn to ¥700bn, within a plan for business profit above ¥330bn on revenue above ¥3.3tn.
Carna Biosciences will supply monzosertib and bear study costs in a Phase 1b trial at MD Anderson for relapsed or refractory AML, now under a signed contract; the notice reports no patient entry or results, and Carna will not routinely announce registry updates.
J-Pharma's Phase 3 biliary cancer trial was selected for AMED support covering half of eligible costs, up to ¥1.5bn, and the company says full payment would fund Part A without new financing.
Kansai Electric's Kanto Hapi e Plus basic charge goes to ¥1,071.65 from ¥830.72 for contracts of 6kW or less on November 1, while its per-kWh rates move only slightly, in line with revised wheeling terms.
Rohto Pharmaceutical lifted its 2030 sales target to ¥444.0bn from ¥415.0bn while lowering the margin goal to 12.8% from 13%, and set 2031 targets including a 40% dividend payout ratio.
JCR Pharmaceuticals will keep manufacturing JR-141 while Italfarmaco takes over sales in the US, Europe and Latin America after approvals, with the upfront payment already in JCR's current-year forecast.
Otsuka says Taiho has begun an FDA application for zipalertinib with chemotherapy in untreated EGFR exon 20 lung cancer, with the filing due to finish by end-2026 and no change to the company's current-year forecast.
Insource's president says large-company demand for basic generative-AI training has peaked and advanced AI arrived slower than planned, and that the trainer will shift to profit-first growth in the year to September 2027 after cutting its outlook.
The satellite company has signed for 20 dedicated Electron launches between 2028 and 2031, and says the deal does not change its December-year guidance.
Astroscale's UK subsidiary signed a £15mn multiyear contract with the Ministry of Defence, but the deal sits outside the forecast for the year to April 2027, and its effect on guidance is still under review.